AAV Vector Production CDMO Services

At ProBioGen, we are dedicated to advancing gene therapy and research through the development and production of high-quality AAV (adeno-associated virus) vectors. Our expertise, our cutting-edge technology, and our commitment to quality make us your ideal partner for your AAV vector production.

We offer flexible, scalable solutions designed to meet the specific requirements of your project, from research and development to clinical trials and therapeutic applications.

AAV Vector Design and Development

AAV Process Development

AAV Vector Manufacturing

AAV Technology Transfer

AAV Analytics

Fast Track & Small Scale: Transient Transfection

When to Adopt This Approach:

This method is widely used due to its flexibility and ability to produce AAV fast and in the short term. It is ideal for preclinical research, proof-of-concept studies, and projects that require rapid turnaround times. Our optimized transient transfection protocols ensure consistent, high-titer vector yields, which helps streamline your research and development workflows.

Production Scale: Preclinical Research Production or GMP-Grade AAV Manufacturing
For preclinical research, we can already offer scalable AAV production in bioreactors of up to 25L. This provides an efficient and cost-effective solution for early-stage projects that require higher yields than traditional small-scale production methods. We use wave, orbital shaken, and stirred tank bioreactors, depending on the customer's needs.

Our GMP-compliant facility, currently in development, will include a 200L bioreactor designed for large-scale production, supporting both clinical trials and commercial demands. This scalable solution ensures seamless project progression, from preclinical research to clinical application, while maintaining full regulatory compliance.

Stable Production at Larger Scale: Packaging Cell Line*

When to Adopt This Approach:

For scalable vector production, we will be able to offer AAV generation through established packaging cell lines in the near future. This approach is preferred for large-scale and clinical-grade projects as it offers batch-to-batch consistency and scalability, making it ideal for high-demand applications and commercial production.

Production Scale: GMP-Grade AAV Manufacturing
Our GMP-compliant facility, currently under development, will feature a 200L bioreactor for large-scale production to support clinical trials and commercial needs. With this scalable solution, your project will grow seamlessly, from preclinical research to clinical application, with full regulatory compliance.

*Coming Soon

Our Proprietary HEK 293 Cell Line

Our AAV production is powered by our proprietary HEK293 cell line, which has been optimized for growth in suspension in chemically-defined mediums. This ensures a robust, scalable, and high-efficiency production platform for AAV vectors. Our cell line is prepared as a master cell bank (MCB), thereby ensuring a consistent and high-quality source for vector production across all projects, from early-stage research to GMP-grade manufacturing.

Stable AAV Packaging Cell Line*

We will soon be able to offer a next-generation packaging cell line developed specifically for AAV production. Based on our optimized starter cell line and professional cloning methods including the proprietary DirectedLuck^® transposase system, our innovative cell line is engineered to provide exceptional performance, reliability, and scalability, making it an ideal choice for researchers and developers in the biotechnology and pharmaceutical industries.

*Coming Soon